Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma
2017-003699-30Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by BeiGene. Primary endpoint: Overall survival in the intention-to-treat population. Started Jan 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2017-003699-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003699-30.